Lilly's Phase 3 study shows significant hair regrowth in adolescent alopecia areata patients with baricitinib.

From Nasdaq: 2025-03-08 21:35:52

Eli Lilly and Co. and Incyte’s Phase 3 BRAVE-AA-PEDS study showed significant improvements in hair regrowth in adolescent patients with severe alopecia areata treated with baricitinib. Results presented at AAD Annual Meeting in Orlando. Study included 257 patients with severe hair loss at baseline. At Week 36, 60.0% on baricitinib 4 mg and 36.9% on baricitinib 2 mg saw at least 50% improvement, compared to 5.7% on placebo. Baricitinib also led to significant eyebrow and eyelash regrowth. Treatment-emergent adverse events included acne, influenza, upper respiratory tract infection. Baricitinib approved by FDA in 2022 for severe AA in adults.



Read more at Nasdaq: Lilly Reveals Positive Phase 3 Results For Adolescent Alopecia Areata Treatment With Baricitinib